According to WHO, Covaxin has 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to its easy storage requirements.
Covaxin vaccine was reviewed by the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE).
Significance
Validation by the WHO is a very significant step towards ensuring global access to India’s widely administered, safe and efficacious Covaxin.